Use of small bowel capsule endoscopy in patients with chronic kidney disease:Experience from a university referral center by Docherty, Emily et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Use of small bowel capsule endoscopy in patients with chronic
kidney disease
Citation for published version:
Docherty, E, Koulaouzidis, A, Douglas, S & Plevris, JN 2015, 'Use of small bowel capsule endoscopy in
patients with chronic kidney disease: Experience from a university referral center' Annals of
Gastroenterology, vol. 28, no. 1, pp. 99-104.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Annals of Gastroenterology
Publisher Rights Statement:
Copyright : © Hellenic Society of Gastroenterology
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-
Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
© 2015 Hellenic Society of Gastroenterology www.annalsgastro.gr
Annals of Gastroenterology (2015) 28, 99-104O R I G I N A L  A R T I C L E
Use of small bowel capsule endoscopy in patients with chronic 
kidney disease: experience from a University Referral Center
Emily Dochertya, Anastasios Koulaouzidisb, Sarah Douglasb, John N. Plevrisa,b
The University of Edinburgh; The Royal Infirmary Edinburgh, Scotland, UK
Abstract Background There are only few reports on the diagnostic yield (DY) of small bowel capsule 
endoscopy (SBCE) in patients with chronic kidney disease (CKD). We aim to report our SBCE 
experience in patients with CKD.
Methods Retrospective study; case notes of patients with low estimated glomerular filtration 
rate (eGFR) who underwent SBCE (March 2005-August 2012) for anemia and/or obscure 
gastrointestinal bleeding (OGIB) were retrieved and abstracted. Severity of CKD was defined 
according to Renal Association recommendations as: stage 3 (eGFR: 30-59); stage 4 (eGFR: 15-29); 
and stage 5 (eGFR <15 or on dialysis).
Results In the aforementioned period, 69 patients with CKD [stage 3: 65/69 (92.8%), stage 4 or 
5:4/69 (7.2%)] had SBCE. 51/65 (78.5%) patients with stage 3 CKD had SBCE due to unexplained 
anemia and/or OGIB [43 (66.1%) and 8 (12.3%), respectively]. In 25/51 (49%), the SBCE was 
normal and in 17/51 (33.3%) showed small-bowel angiectasias. Other findings were active bleeding 
(n=2), fold edema (n=2), ileal erosions (n=1), adenocarcinoma (n=1), and inconclusive/videos 
not available (n=3). All patients (n=4) with CKD grade 4 or 5 were referred due to unexplained 
anemia; 3/4 (75%) had angiectasias and 1 normal SBCE. Fecal calprotectin (FC) was measured in 
12 patients with CKD stage 3 and unexplained anemia prior to their SBCE; no significant small-
bowel inflammation was found in this subgroup. 
Conclusion SBCE has limited DY in CKD patients referred for unexplained anemia. Sinister SB 
pathology is rare, while the most common finding is angiectasias. Furthermore, FC measurement 
prior to SBCE -in this cohort of patients- is not associated with increased DY.
Keywords Capsule endoscopy, chronic kidney disease, obscure gastrointestinal bleeding, anemia, 
fecal calprotectin
Ann Gastroenterol 2015; 28 (1): 99-104
Introduction
Patients with poor renal function frequently present with 
gastrointestinal (GI) complications such as obscure GI bleeding 
(OGIB) (overt and/or occult i.e.  iron-deficiency anemia 
[IDA]), diarrhea, and/or abdominal pains. Therefore, direct 
visualization of the small bowel (SB) often becomes part of the 
necessary diagnostic workup in this patient group. Over more 
than a decade now, SB capsule endoscopy (SBCE) has gained 
a key role in the diagnostic approach of the SB [1]. Conversely, 
the use of SBCE and the characteristics of SB pathology in 
patients with chronic kidney disease (CKD) have been studied 
only in limited number of case series [2-7]. Furthermore, 
there is scarcity of data on the use of fecal calprotectin (FC) 
as selection tool for SBCE [1,8], even more so in patients with 
renal dysfunction who need to be prioritized to SBCE.
An increased prevalence of SB angiectasias has been 
reported in patients with CKD [5]. However, the exact impact 
of these findings, their endoscopic significance/severity grade, 
and furthermore their clinical impact is not well understood. 
Moreover, there is no known clinical indicator/marker when it 
comes to prioritizing these referrals.
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This retrospective study, from a tertiary referral center, 
aimed to evaluate the use of SBCE in a cohort of patients with 
low estimated-glomerular filtration rate (e-GFR). Furthermore, 
we aimed to review the validity of FC in patients with impaired 
renal function who underwent SBCE.
Materials and methods
A review of the SBCE database of our hospital (a University 
hospital and tertiary referral center for capsule endoscopy for 
South East of Scotland, UK) was performed to identify patients 
with low e-GFR who had undergone a SBCE between March 
2005 and August 2012.
The severity of kidney disease was classified in accordance 
with the Renal Association definitions [available from http://
www.renal.org/home#sthash.Nejfpmsh.dpbs] [9]:
Stage 2 (e-GFR=60-89 mL/min/1.73m2): mildly reduced 
kidney function
Stage 3 (e-GFR=30-59 mL/min/1.73m2): moderately 
reduced kidney function
Stage 4 (e-GFR=15-29 mL/min/1.73m2): severely reduced 
kidney function
Stage 5 (e-GFR<15 mL/min/1.73m2 or on hemodialysis): 
very severe, or end-stage kidney failure.
For the purpose of this study, advanced CKD was defined 
as stage 4 or 5 [2]. For each included patient, the e-GFR used 
was defined as the mean value of e-GFR readings over a prior 
5-year period prior to the SBCE.
Data collection
Paper and electronic case notes were retrieved and reviewed. 
Age, gender, hemoglobin (Hb), mean corpuscular volume 
(MCV), platelets (Plt), ferritin, and FC levels were abstracted 
from electronic case notes (in each case, the result closest to the 
date of SBCE was selected). Certain medications that could have 
contributed to complications from SB pathology (i.e. aspirin, 
warfarin, angiotensin-converting enzyme inhibitors) were 
also abstracted, where the info was available. Important co-
morbidities and/or past medical history (diabetes, celiac 
disease, heart failure, heart and/or liver transplant, colectomy) 
and outcome were also noted for each patient.
Indications for SBCE
Indications for SBCE in our cohort were: OGIB; IDA; 
anemia (unspecified); known and/or suspected inflammatory 
bowel disease (IBD); diarrhea; celiac disease (CoD); and weight 
loss. Overt OGIB was defined according to the American 
Gastroenterological Association position statement as bleeding 
manifesting as melena and/or hematochesia and no obvious 
GI cause, following upper and lower GI tract endoscopy [10]. 
IDA was defined as iron deficiency with Hb <120  g/dL for 
women and 135 g/dL for men (as per our laboratory reference 
range) [11,12]. In our center, we do not routinely perform 
SBCE for fecal occult blood tests.
Incomplete SBCE videos, i.e. videos where the capsule failed to 
pass into the cecum during the period of the recording, were not 
excluded from further analysis. The SBCE diagnostic yield (DY) 
for each CKD group was then calculated. SB angiectasias were 
classified according to the established classification for bleeding 
potential as P0 (non-pathological), P1 (low/indeterminate 
bleeding potential), or P2 (high bleeding potential) lesions [13].
SBCE procedure
SBCE was performed with the PillCam® SB1/SB2 (Given® 
Imaging Ltd, Yokneam, Israel) and the MiroCam® (IntroMedic 
Co, Seoul, South Korea) capsule endoscopes using the predefined 
for our unit regular procedure protocol, i.e., strict liquid diet the 
day prior to the test and SB purge (2 L polyethylene glycol; PEG, 
Moviprep®) with overnight fast. Hemodialysis patients were not 
given any PEG preparation, due to restriction of fluid intake; 
instead, they were placed on strict liquid diet the day before 
the procedure. In our center, capsule ingestion is performed 
with 40-100 mg of anti-foam (Simeticone, Infacol®) and 5 mg 
of liquid prokinetic (domperidone), unless in exceptional 
circumstances. The patients are allowed to drink clear fluids 
after 2 h and consume a light meal/snack after 4 h. All videos 
were re-checked (for the purpose of this study) by an expert 
capsule endoscopist (AK; experience >1,500 reviews).
Statistical analysis
Continuous data are expressed as mean ± SD (range) to 
one decimal place. Differences between groups were evaluated 
using chi-squared (χ2) test for categorical variables and 
Student’s two-sample t-test for continuous variables following 
a normal distribution or the Mann-Whitney U-test for those 
who failed the normality test. A P value <0.05 was considered 
statistically significant.
This study was conducted in accordance with UK research 
ethics guidelines. After review by the local ethics committee 
further specific ethical review and approval were not required, 
as the study was considered an evaluation of previously 
collected endoscopy images, using data already obtained as 
part of regular clinical care [12].
Results
Demographics
A total of 69 patients with low eGFR (<60 mL/min/1.73 m2), 
who had undergone SBCE, were identified. 65  patients 
with moderate CKD i.e.  stage 3  (20  males/45  females) were 
found; the rest (n=4) had severe CKD. Eleven patients were 
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also suffering from liver complications – (cirrhosis n=4, 
liver fibrosis n=2, autoimmune hepatitis n=1). 4/11  (36.3%) 
patients [eGFR 41±8.780  (29-49) mL/min/1.73m2] had 
undergone a liver transplant prior to having a SBCE: Hb levels 
90.8±17.7  (76-114) g/L; MCV levels 80.3±6.9  (72-88) fL; Plt 
count 284.0±86.6  (201-389) x 109/L; and ferritin 30.0±31.1 
(8-52) µg/L. 2/4  (50.0%) of the liver transplant patients were 
referred for IDA with SBCE findings of non-specific fold 
edema (n=1) and normal (n=1). The remaining 2/4  (50%) 
liver transplant patients were referred for diarrhea, with SBCE 
findings of non-specific fold edema (n=1) and normal (n=1).
One female patient had undergone heart transplantation 
11 years prior to having SBCE. A mean eGFR of 59 mL/min/1.73 m2 
placed her in the top end of stage 3 CKD. She was referred for 
IDA, her capsule reported non-specific fold edema.
Other important medical history and complications were 
found in 7/69 (10.1%) patients: colectomy for ulcerative colitis 
(n=4), adenocarcinoma of the kidney (n=2), and heart failure 
(n=1). Overall, there was no statistical difference with regard 
to demographics, medications used, prior comorbidities (apart 
from CKD), and prior history of transplant operations (Table 1).
CKD stage 3 subgroup (moderate CKD)
In this subgroup, the mean e-GFR (calculated from 
each patient’s individual 5-year average value) was 49±7.9 
(30-59) mL/min/1.73  m2. The most common indication 
for referral to SBCE was OGIB (78.5%; n=51); IDA (66.1%; 
n=43); and/or clearly defined overt-OGIB (12.3%; n=8). 
Fourteen (21.5%) patients were referred for indications 
other than OGIB (diarrhea, abdominal pain, and/or weight 
loss). The mean Hb level was: 100.8±19.8  g/L, MCV: 
86.5±7.8 fl, Plt count: 244.9±105.8 x 109/L, and ferritin: 
116.0±337.0 µg/L.
In the OGIB group, 49.0% (n=25) had normal SBCE, 
while 33.3% (n=17) had angiectasias (P2 lesions: n=5), active 
bleeding (n=2), mucosal fold/villous edema (n=2), ileal 
erosions (n=1), adenocarcinoma (n=1), and inconclusive/
non-available videos (n=3), (Table 2). The majority, 64.2% 
(n=9) of those referred for indication other than OGIB had 
normal SBCE. Angiectasias were uncommon in this group 
(n=1) (Table 2). Furthermore, there was no SBCE-related 
mortality.
CKD stage 4/5 subgroup (severe CKD)
4  patients had CKD stage 4 (n=3; 1M/2F) or 5 
(n=1M); in CKD stage 4 the mean eGFR was 27±2.3 
(25-29) mL/min/1.73m2. The patient with CKD stage 5 was 
on dialysis and had an eGFR of <5 mL/min/1.73m2. Two 
of the 3  (66.7%) patients with CKD stage 4  patients were 
referred for IDA and the other for diarrhea. The patient 
with CKD stage 5 was referred for normocytic anemia. 
In CKD stage 4 group, the mean Hb was: 85.3±21.2  g/L, 
MCV: 86.0±7.550 fl, Plt: 269.3±103.7×109/L, ferritin: 
251.0±333.5  µg/L. The patient in CKD group stage 5 had 
Hb: 95.0  g/L, MCV: 95.0 fl, Plt: 258.0×109/L, and ferritin: 
191 µg/L.
In the CKD stage 4 group, the SBCE showed angiectasias 
(ranging from P0 to P2, with only 1 P2 lesion); the other SBCE 
was normal. In the single patient on hemodialysis, SBCE 
encountered only jejunal angiectasias (P0).
Overall, there was no difference in the positive DY, 
i.e.  sinister and non-sinister findings (P=0.43) between the 2 
subgroups of patients with CKD.
Fecal calprotectin (FC)
12/65  (18.4%) patients (2  males/10  females) with CKD 
stage 3 [eGFR 51±8.019  (38-59) mL/min/1.73m2] had FC 
performed in the pre-referral workup. In this subgroup, mean 
Hb was 111.5±18.9 (76-136) g/L; MCV 91.2±6.3 (80-102) fL; Plt 
249.1±94.8 (77-395) x 109/L; and ferritin 61.3±86.1 (11-271) µg/L 
levels all lay within their respective reference ranges.
In this subgroup, no sinister pathology or SB inflammation 
was found; 5/12 (41.7%) SBCE were normal, 3/12 (25.0%) found 
angiectasias (3/3 grade  P1), 1/12  (8.3%) found non-specific 
fold edema, and 3/12 (25.0%) capsules were incomplete.
Therefore, there was no statistically significant difference 
between the DY of patients who had FC measurement prior 
to their SBCE and the rest of the patients with CKD stage 3, 
P=0.25.
Table 1 Patient demographics and clinical characteristics
Severe CKD Non-severe CKD
Stage 5 Stage 4 Stage 3 P value
Demographics 
No. of patients 1 3 65
Mean age (years)±SD 
Gender: M/F 1/0 1/2 21/44 0.596
Medications
Aspirin 0 1 27 0.642
ACE-inhibitors 0 2 29 1.0
Warfarin 0 0 9 1.0
Co-morbidities
Diabetes mellitus 0 0 26 0.289
Celiac disease 0 0 5 1.0
Heart failure 0 0 12 1.0
Past surgical history
Organ transplant 0 0
Heart transplant 0 0 1 1.0
Kidney transplant 0 0 1 1.0
Liver transplant 0 0 4 1.0
Colectomy (for UC) 0 0 4 1.0
CKD, chronic kidney disease; No, number; SD, standard deviation; M/F, males/
females; ACE, angiotensin-converting enzyme; UC, ulcerative colitis 
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Other complications
Post-SBCE In CKD stage 3 group, 11/65  (16.9%) patients 
died (range: 0-34  months). Three deaths were attributed 
directly to the renal failure and 1 was reported to be due to a 
coronary event secondary to SB angiectasia bleeding. In CKD 
stage 4 group, 2/3 of the patients subsequently died (29 and 
11  months post-SBCE, respectively); the cause of death was 
unrelated to the SBCE and/or any SB pathology.
Discussion
In the present study, we included 69  patients with 
moderate-severe CKD. In half of the cases (50.7%; n=35), 
the SBCE was normal/negative DY. In those with positive 
DY, the commonest SB finding was angiectasias (of any 
P-grade); 30.4% (n=21). The overall positive DY for this study 
(non-sinister pathology; angiectasia and active bleeding) 
was 23/69  (33.3%), which correlates with previous studies 
(Table  2). After excluding 6 SBCE, due to the fact that the 
videos were not available at the time of this study for review, 
the majority of patients (62/63; 98.4%) had a non-sinister 
SBCE diagnosis (Table 2). Findings of angiectasias were even 
lower in the subgroup of patients with high FC levels: DY of 
25%, suggesting the limited use that FC has as an indicator 
of SB pathology, hence selection tool for SBCE, in patients 
with CKD.
Chalasani et al [14] suggest that there is a direct relation 
between prevalence of angiodysplasia and both the severity 
and duration of CKD. Indeed, in our study, clinically 
significant angiectasias i.e.  P1/P2-grade, were found in 
75% of patients with CKD stage 4 or 5 and angiectasias, 
as compared to 27.7% in patients of CKD stage 3, P<0.05. 
However, our CKD groups  4 and 5 consisted of just 
4 patients. Conversely, Holleran et al [5] suggested that the 
development of SB angiodysplasia occurs early in the natural 
history of CKD, supporting the clinical validity of SBCE in 
this group of patients.
Only a limited number of studies looked into the use of 
diagnostic SBCE in patients with CKD. The majority of them 
showed a high DY with regards to SB pathology that could 
be contributing to OGIB e.g.  angiectasias, active bleeding 
(Table  3). A  study by Karagiannis et al [2] reported positive 
findings i.e. angiectasias in 47% of patients with CKD stage 4. 
Conversely, in the non-CKD patients the positive findings were 
only 17.6%. The number of these CKD patients totalled 17; 7 
pre-dialysis, 4 on maintenance hemodialysis, 6 renal transplant 
recipients. Their results have been later confirmed by Sidhu 
et al [6]; these authors reported a DY of 33% (angiectasias) in 
patients with CKD (Table 3).
SB angiectasias can account for up to 40% of SB causes of 
OGIB [15]. However, up to 90% of them can spontaneously 
stop bleeding. This suggests that a finding of angiectasias in 
a patient with CKD does not necessarily mean it is the cause 
of unexplained anemia. This, combined with our 33.3% DY of 
angiectasias in patients with CKD, suggests that CE is not of 
especially significant use in diagnosing unexplained anemia in 
patients with CKD. There are of course other causes of anemia 
in patients with CKD: low erythropoietin production, uremic 
toxicity, low Plt production, poor GI absorption of iron etc. 
which should be fully investigated, perhaps before suggesting 
OGIB as the cause.
Our study was limited to patients with CKD, and did not 
compare the diagnostic yield of SBCE to a group of patients 
Table 2 Table showing the DY per indication for patients with CKD stage 3, stage 4, and stage 5
Indication DY Total
(+) DY
Non-sinister 
pathology*
Sinister 
pathology**
Normal 
SBCE
Other 
findings***
Inconclusive/not 
available for review
CKD Stage 3
IDA±OGIB 19 1 25 3 3 23
Anemia 1 0 3 0 0 1
Diarrhea 0 0 3 1 2 3
IBD 0 0 2 0 0 0
Celiac disease 0 0 1 0 0 0
Weight loss 0 0 0 0 1 0
CKD Stage 4
IDA±OGIB 2 0 0 0 0 2
Diarrhea 0 0 1 0 0
CKD Stage 5
Anemia 1 0 0 0 0 1
CKD, chronic kidney disease; IDA, iron-deficiency anemia; OGIB, obscure gastrointestinal bleeding; IBD, inflammatory bowel disease; DY, diagnostic yield 
*non-sinister pathology = angiectasias and/or active bleeding, **Sinister pathology = adenocarcinoma, ***Other findings = inflammatory-type of lesions i.e. 
mucosal fold edema and/or ileal erosions
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without CKD. The difference in group sizes between CKD 3 
and CKD 4/5, as mentioned above, presented difficulties in 
result comparisons and should be investigated with higher 
numbers.
In conclusion, SBCE endoscopy has limited DY in CKD 
patients referred for investigation of unexplained anemia. The 
most common finding is angiectasias, while sinister bowel 
pathology is rare. Furthermore, FC measurement pre-SBCE is 
not associated with increased DY.
Table 3 Comparison of DY of SBCE in patients with CKD between recent studies
Authors, year, [ref] Patients 
with CKD
Type of 
capsule
Indications Severity of CKD DY DY criteria
Docherty et al 69 PillCam®SB OGIB CKD 3, 4 and 5 33.3% Angiectasias and/or 
active bleeding
Sidhu et al [5] 26 n/a OGIB - 33% Angiectasias
Karagiannis 
et al [2]
17 M2A® OGIB CKD 4 and 5 47% Angiodysplasia
Sakai et al [4] 44 PillCam®SB OGIB This paper 
did not look 
specifically into 
patients with 
CKD
20.2 % (This 
includes non CKD 
patients 148/242 – 
data for just CKD 
not available)
Vascular lesions
Ohmori et al [3] 13 PillCam®SB OGIB Hemodialysis 61.5% Vascular lesions
Kawamura 
et al [7]
14 PillCam®SB OGIB CKD stages 4 
and 5
47.6% Vascular lesions
ref, reference; CKD, chronic kidney disease; IDA, iron-deficiency anemia; OGIB, obscure gastrointestinal bleeding; IBD, inflammatory bowel disease; DY, diagnostic yield
Summary Box
What is already known:
•	 Patients	 with	 poor	 renal	 function	 frequently	
present with obscure gastrointestinal bleeding
•	 Increased	 prevalence	 of	 small	 bowel	 (SB)	
angiectasias has been reported in patients with 
chronic kidney disease (CKD)
•	 There	 is	 only	 a	 limited	 number	 of	 studies/case	
series in the use of SB capsule endoscopy (SBCE) 
in patients with CKD
•	 There	 is	 scarcity	 of	 data	 on	 the	 use	 of	 fecal	
calprotectin (FC) as selection tool for SBCE
What the new findings are:
•	 SBCE	endoscopy	has	a	limited	diagnostic	yield	in	
patients with CKD referred for investigation of 
unexplained anemia
•	 The	most	 common	 finding	 is	 angiectasias,	 while	
sinister bowel pathology is rare
•	 Furthermore	 in	 CKD	 patients,	 FC	measurement	
pre-SBCE is not associated with increased DY
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